Igor Splawski News Today

CureVac N.V. Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income ...

Issuer: CureVac / Key word: Personnel CureVac Announces Update to the Management Team 14.07.2023 / 13:00 CET/CEST The issuer is solely responsible for...

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 14, 2023 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on

Issuer: CureVac / Key word(s): Interim Report/Study CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Developme...

Investegate announcements from CureVac, CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs

Promising COVID-19 and flu modified mRNA vaccine candidates identified based on positive preliminary data from ongoing Phase 1 studiesAll candidates use CureVac's advanced second-generation mRNA backbone

Investegate announcements from CureVac, CureVac and GSKs Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study

- Vaccine candidate combining Beta- and Delta-specific mRNAs shows strong protection and immune responses during preclinical challenge study- Demonstrated neutralizing capacity against the Omicron variant

Issuer: CureVac / Key word(s): Study21.04.2022 / 13:00 The issuer is solely responsible for the content of this announcement.CureVac and GSK's Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study- Vaccine candidate combining Beta- and Delta-...

21.04.2022 - - Vaccine candidate combining Beta- and Delta-specific mRNAs shows strong protection and immune responses during preclinical challenge study- Demonstrated neutralizing capacity against the Omicron variant in vaccinated animals- Technology adaptation ... Seite 1